FDA Inspection 1252996 — Anna Dryja, MD, MBA
The FDA completed an inspection of Anna Dryja, MD, MBA on Oct 18, 2024 in Warsaw. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Oct 18, 2024
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Warsaw (Poland)
Additional details
Clinical BA/BE